PER 2.41% 8.1¢ percheron therapeutics limited

Will PER follow DXB on a similar journey ?, page-4

  1. 900 Posts.
    lightbulb Created with Sketch. 103
    The failure of other drugs could be a double edged sword for PER.

    On the plus side, it reduces competition for us.
    On the other side, it could make potential PER partners cautious because this is a tough disease to crack and littered with failed trials.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.